HELP YOUR ADULT PATIENTS WITH NMOSD

BE UP FOR

grabbing tomorrow

AND MAKING IT THEIRS

HELP YOUR ADULT PATIENTS WITH NMOSD

BE UP FOR

grabbing tomorrow

AND MAKING IT THEIRS

EFFICACY

Relapse reduction

89%

of patients on Uplizna™ (inebilizumab-cdon) were relapse-free at 28 weeks

58%

for placebo¹


Significantly longer time to first adjudicated neuromyelitis optica spectrum disorder (NMOSD) relapse for Uplizna vs placebo in the randomized-controlled period (ITT* population; anti-aquaporin-4 [AQP4] antibody positive patients)

Kaplan Meier curve: time to first relapse Kaplan Meier curve: time to first relapse Kaplan Meier curve: time to first relapse
Hospital

Reduced hospitalizations

Uplizna reduced the annualized rate of hospitalization for anti-AQP4 antibody positive patients vs placebo¹

78%

relative reduction in the annualized rate of hospitalization for Uplizna vs placebo (0.11 vs 0.5 for placebo)¹

SAFETY

Uplizna has a favorable safety profile

Uplizna is contraindicated in patients with¹:

  • A history of life-threatening infusion reactions to Uplizna
  • Active hepatitis B infection
  • Active or untreated latent tuberculosis

Uplizna has a similar adverse event rate compared to placebo1,2

Adverse reactions in adult patients with NMOSD with an incidence of at least 5% with Uplizna and a greater incidence than placebo¹

Adverse Reactions Uplizna (n=161) % Placebo (n=52) %
Urinary tract infection 11 10
Arthralgia 10 4
Headache 8 8
Back pain 7 4
Adverse Reactions
Urinary tract infection

Uplizna (n=161) %
11

Placebo (n=52) %
10

Adverse Reactions
Arthralgia

Uplizna (n=161) %
10

Placebo (n=52) %
4

Adverse Reactions
Headache

Uplizna (n=161) %
8

Placebo (n=52) %
8

Adverse Reactions
Back pain

Uplizna (n=161) %
7

Placebo (n=52) %
4

Uplizna can cause serious adverse events, including infusion reactions, infections, reduction in immunoglobulins and fetal risk. For more information about possible serious adverse events, please see Prescribing Information.

Additional safety considerations

  • Consider the risk for increased immunosuppressive effects when used in combination with other immunosuppressant therapies¹
  • Women of childbearing age should use contraception while receiving Uplizna and for six months after the last infusion¹
  • Infusion reactions were most common with the first infusion (9.3%), but were also observed during subsequent infusions¹
    • Most infusion reactions were mild to moderate. Symptoms included headache, nausea, somnolence, dyspnea, fever, myalgia, rash or other signs or symptoms1,3

Infection was reported in 39% of Uplizna patients and 44% of placebo patients during the randomized-controlled period³

Immunoglobulins¹

  • Consistent with its mechanism of action, average immunoglobulin levels decreased with Uplizna use
  • The proportion of Uplizna-treated patients with immunoglobulin G (IgG) levels below the lower limit of normal at year one was 7.5% and at year two was 14%
  • The relationship between reduced immunoglobulin levels and infection has not been assessed with Uplizna

Neutropenia¹

  • Neutropenia was generally transient and was not associated with serious infections
Support programs

Access and Support

Get personalized support for you and your patients with Viela VIPs.

Viela VIPs Personal Support
Patient resources

Resources for Your Patients

Conversation guides and downloadable materials to help inform and educate your patients about Uplizna.

See patient resources

Stay Up to Date

Register to receive more information about Uplizna.

Register now

References: 1. Uplizna [prescribing information]. Gaithersburg, MD: Viela Bio; June 2020. 2. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised, placebo-controlled phase 2/3 trial. Lancet. 2019;394:1352-1363. doi: 10.1016/S0140-6736(19)31817-3. 3. Data on file. Viela Bio.